TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07545811: Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Janux Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 43 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT07545811 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07545811 Rescue Dossier →